Showing 1 - 10 of 76
pharmaceuticals. We challenge this orthodox view and show, to the contrary, that the pace of innovation often is faster in a world …
Persistent link: https://www.econbiz.de/10005666872
We study the incentives that governments have to protect intellectual property in a trading world economy. We consider a world economy with ongoing innovation in two countries that differ in market size, in their capacities for innovation and in their absolute and comparative advantage in...
Persistent link: https://www.econbiz.de/10005792347
We present a Hotelling model of price and advertising competition between prescription drugs that differ in quality/side e¤ects. Advertising results in the endogenous formation of two consumer groups: brand loyal and non-brand loyal ones. We show that advertising strategies are strategic...
Persistent link: https://www.econbiz.de/10008680762
pharmaceuticals, specifically drug reformulation regulatory gaming. …
Persistent link: https://www.econbiz.de/10009205060
treatments. The TRIPS Agreement, which specifies minimum levels of intellectual property protection for countries in the World …
Persistent link: https://www.econbiz.de/10009002387
the hypothesis that innovation in pharmaceuticals is becoming more difficult and expensive over time, as costs of …
Persistent link: https://www.econbiz.de/10009003149
creating an internal market for pharmaceuticals can be analysed. In a model of third-degree price discrimination, arbitrage … Market in pharmaceuticals are ambiguous, since a movement from segmented and price-controlled markets towards integrated …
Persistent link: https://www.econbiz.de/10005114350
Preventives are sold ex ante, before disease status is realized, while treatments are sold ex post. Even if the mean of the ex ante distribution of consumer values is the same as that ex post, the shape of the distributions may differ, generating a difference between the surplus each product can...
Persistent link: https://www.econbiz.de/10011196028
We provide a method allowing to identify margins in an oligopoly price competition game when prices may not be freely chosen in some markets, for example due to regulation. We use our identification strategy to study the effects of regulatory constraints in the pharmaceutical industry, which is...
Persistent link: https://www.econbiz.de/10011083879
We develop a North-South model of reciprocal antidumping (AD). We find that AD wars are winnable for the Northern firm if the Southern market is sufficiently small relative to the North’s. The South can avert AD war with the North by expanding the home market size. It may however trigger AD...
Persistent link: https://www.econbiz.de/10008554221